Smart Protocols. Because Every Body Is Different.

Bringing Injection Protocol Personalisation to Clinical Routine

Every day, a diverse patient population presents unique imaging challenges. It is well accepted that contrast enhancement decreases with increasing patient size and that individualised protocols can lead to more consistent images.[1,2,3,4]



However, individualising protocols for every patient's exam has been considered impractical. Numerous factors related to the patient and to the procedure lead to complex manual calculations or look-up tables, which can take up valuable time and potentially lead to mistakes. And as scanner technology has advanced, the ability to use lower tube voltages to reduce radiation dose to patients has made protocoling even more complicated. To maintain similar levels of contrast enhancement across different tube voltages, the iodine delivery rate and iodine load should be adjusted, as well.[5] All of this can be overwhelming to a radiology department already stretched thin.

Patient-centric Workflow for Individualised Care

Bayer's MEDRAD® Centargo CT injection system is now available with Workflow Solutions //Smart Protocols software, streamlining the personalisation process into a few clear steps.

//Smart Protocols

Gives You Control

- Implement your site's preferred dosing options and limits, based on your own injection protocols, for as many indications as you need
- Review what has been adjusted and what limits are in effect as the protocol is automatically recalculated

Enables Routine Personalisation

- Automatically calculate flow rates and volumes based on patient size (weight or lean body weight) and contrast media concentration
- Apply tube voltage adjustment to account for scanner settings

Provides Added Confidence

- Display site-specific eGFR guidance before the protocol is even selected
- Verify that calculated flow rates and pressure limit settings comply with your policies for IV access

1. Apply exam-time check of eGFR according to site guidance

2. Calculate injection protocol based on patient, contrast media concentration and tube voltage

3. Verify that the protocol settings comply with IV access policies

Injector and Contrast Media Considerations for Personalised Protocols

With a modern, streamlined user interface, modality worklist integration[6] and built-in barcode reader, Centargo easily incorporates //Smart Protocols into the workflow. Combined with Ultravist's (iopromide) 2D barcode for automatic data entry, getting the information required to personalise protocols could not be simpler.

PBS Information: This product is not listed on the PBS.

ULTRAVIST® (iopromide)
INDICATIONS: ULTRAVIST is indicated for all angiographic and urographic examinations and for contrast enhancement in computerised tomography. ULTRAVIST 240 is additionally indicated for lumbar myelography in adults. CONTRAINDICATIONS: known hypersensitivity or previous reaction to iodinated contrast media or excipients, immediate repeat myelography. PRECAUTIONS: anaphylactoid/hypersensitivity or other idiosyncratic reactions; pretesting/sensitivity testing is not recommended, evaluate potential risk of hypothyroidism in patients with known or suspected thyroid dysfunction, monitor thyroid function in neonates who have been exposed to ULTRAVIST; patients with CNS disorders, exercise caution in situations of reduced seizure threshold; patients with pronounced states of excitement, anxiety and pain; patients with significant cardiac disease or severe coronary artery disease; thromboembolic events; patients with severely impaired renal function, combined renal and hepatic disease, combined renal and cardiac disease, anuria or when large doses are administered; ensure adequate hydration status before i.v. or i.t. administration to minimise PC-AKI and especially in renally impaired patients; patients with known or suspected pheochromocytoma; intravascular use in patients with autoimmune disorders, myasthenia gravis, cerebral angiography or peripheral angiography; intrathecal use in patients with seizure history; not for use in thoracic, cervical or total columnar myelography, cerebral ventriculography or cisternography; paediatrics; pregnancy (Category B2); effects on diagnosis and treatment of thyroid disorders with thyrotropic radioisotopes; avoid driving or operating machinery for the first 24 h after administration. INTERACTIONS WITH OTHER MEDICINES: metformin; neuroleptics and antidepressants; beta-blockers; interleukin-2. ADVERSE EFFECTS: Common: dizziness, headache, dysgeusia, blurred/disturbed vision, chest pain/discomfort, hypertension, vasodilation, vomiting, nausea, pain, injection site reactions, feeling hot. Refer to full PI for a complete list. DOSAGE AND ADMINISTRATION: Dosage should be adapted to age, weight, clinical question, examination technique and region to be investigated. Can be used with single-use or multi-patient use injector system. Administration may be intravascular or intrathecal depending on clinical problem and region to be investigated. For intrathecal use in myelography, only ULTRAVIST 240 is recommended and allow at least 48 h before repeat examination. Refer to full PI for details. DATE OF PREPARATION: Based on PI dated 17 November 2021.

Please review the full Product Information before prescribing.
Approved PI available at https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf?OpenAgent&id=CP-2020-PI-02293-1
or upon request from Bayer Australia Ltd, ABN 22 000 138 714, 875 Pacific Highway, Pymble NSW 2073, phone 1800 008 757.

® Registered trademark of the Bayer Group, Germany

References

1. Mihl C et al. Evaluation of individually body weight adapted contrast media injection in coronary CT-angiography. Eur J Radiol. 2016;85(4):830-6. doi: https://doi.org/10.1016/j.ejrad.2015.12.031
2. Martens B et al. Individually Body Weight-Adapted Contrast Media Application in Computed Tomography Imaging of the Liver at 90 kVp. Invest Radiol. 2019;54(3):177-182. doi: https://doi.org/10.1097/rli.0000000000000525.
3. Hendriks BMF et al. Individually tailored contrast enhancement in CT pulmonary angiography. Br J Radiol. 2016;89(1061):20150850. doi: https://doi.org/10.1259/bjr.20150850
4. Seifarth H et al. Introduction of an individually optimised protocol for the injection of contrast medium for coronary CT angiography. Eur Radiol. 2009;19(10):2373-82. doi: https://doi.org/10.1007/s00330-009-1421-7
5. Hendriks BMF et al.Optimising Pulmonary Embolism Computed Tomography in the Age of Individualised Medicine: A Prospective Clinical Study. Invest Radiol. 2018;53(5):306-312. doi: https://doi.org/10.1097/rli.0000000000000443
6. In conjunction with additional purchase of Automated Documentation

Clear Direction. From Diagnosis to Care.

CE 2797

Radiology
Bayer Australia Ltd
875 Pacific Highway
Pymble NSW 2073
Australia
Phone: 1800 008 757
ABN: 22 000 138 714

Manufacturer
Imaxeon Pty Ltd
Unit 1, 38 – 46 South Street
Rydalmere, NSW 2116
Australia
Phone: 02 8845 4999
Fax: 02 8845 4936
Imaxeon is a Bayer subsidiary

Australian Sponsor
Imaxeon Pty Ltd
Unit 1, 38 – 46 South Street
Rydalmere, NSW 2116
Australia
Phone: 02 8845 4999
Fax: 02 8845 4936
Customer Service: 1800 633 723

More information on
radiology.bayer.com.au

PP-M-CEN-AU-0042-1
Date of preparation October 2021